CBPE acquired Rosemont in August 2006 for £93m.
The sale to Perrigo represents an investment multiple of 3.25x CBPE’s £52m equity investment over the investment period for CBPE’s investors.
Rosemont develops, manufactures and supplies oral liquid medicines for patients who have difficulty in swallowing tablets and capsules.
The firm supplies its products through hospitals, wholesalers and retail pharmacies.
CBPE partner Sean Dinnen said, "We are very pleased with the significant progress Rosemont has made, which illustrates the strength of our investment strategy and the long term approach we take to our portfolio companies, supporting management to build a truly world class business."